Sars-Cov-2
Since November 2019, cases of lethal infection associated with a new coronavirus, SARS-Cov-2 (COVID-19), have occurred in China, and then rapidly in several countries around the world.. At the time of writing this article are recorded about 3.7 million infected in the world with about 1.25 million healed and about 265 thousand deaths. This global pandemic has triggered a global health crisis with few precedents in human history. From the various studies carried out, the phase of the infection has been divided into three phases, the first with mild or absent symptoms where the immune system fights the virus, the second where the symptomatology is more serious and there is a hyperactive inflammatory system, the third where the immune system is altered and there is a generalized inflammatory state that can cause serious and fatal lung lesions and multi-organ dysfunction. (1-2) To date, there are no vaccines for the virus, nor direct antivirals. The drugs used are registered antivirals for other viral infections, or drugs that act on the generalized inflammatory state such as immunomodulants. While we are waiting for the discovery of an effective vaccine or direct antiviral against Sars-cov-2 soon, excellent hopes come from the passive immunization of the infected patient with the administration of convalescent plasma from patients already cured of the infection. The Plasma therapy (PT) has already shown benefits in the treatment of prophylaxis and treatment for Sars-Cov-2 infection.(3-4)